Children, although at lower risk of poor outcomes from COVID-19 relative to adults, still stand to benefit from therapeutic interventions. Understanding of COVID-19 clinical presentation and prognosis in children is essential to optimize therapeutic trials design. This perspective illustrates how to collectively accelerate pediatric COVID-19 therapeutic research and development, based on the experience of the Global Accelerator for Paediatric Formulations.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Therapeutics, research and development, pediatrics, 【초록키워드】 Trial, Prognosis, pediatric, children, research and development, outcome, Adults, therapeutic, Research, understanding, therapeutic trials, Perspective, lower risk, therapeutic interventions, benefit, accelerate, Accelerator, 【제목키워드】 research and development, access, development, opportunity, right,
【저자키워드】 COVID-19, SARS-CoV-2, Therapeutics, research and development, pediatrics, 【초록키워드】 Trial, Prognosis, pediatric, children, research and development, outcome, Adults, therapeutic, Research, understanding, therapeutic trials, Perspective, lower risk, therapeutic interventions, benefit, accelerate, Accelerator, 【제목키워드】 research and development, access, development, opportunity, right,
어린이는 성인에 비해 COVID-19로 인한 좋지 않은 결과의 위험이 낮지만 여전히 치료적 개입의 이점을 누릴 수 있습니다. 치료 시험 설계를 최적화하려면 소아에서 COVID-19 임상 증상 및 예후를 이해하는 것이 필수적입니다. 이 관점은 Global Accelerator for Pediatric Formulations의 경험을 바탕으로 소아 COVID-19 치료 연구 및 개발을 집합적으로 가속화하는 방법을 보여줍니다.